[1]. Yu MC. Diet and nasopharyngeal carcinoma. Prog Clin Biol Res. 1990;346:93–105.
[2]. Chan AT, Teo PM, Johnson PJ. Nasopharyngeal carcinoma. Ann Oncol 2002; 13: 1007-1015. 10.1093/annonc/mdf179
[3]. Wani S Q, Khan T, Wani S Y, et al. Nasopharyngeal Carcinoma: A 15Year Study with Respect to Clinicodemography and Survival Analysis[J]. Indian Journal of Otolaryngology & Head & Neck Surgery, 2016; 68(4):1-11.
[4]. Ma C, Mok E, Kapur A, et al. Clinical implementation of a Monte Carlo treatment planning system[J]. Med Phys 1999; 26(10):2133–2143.
[5]. Denis F, Garaud P, Bardet E, et al. Final Results of the 94–01 French Head and Neck Oncology and Radiotherapy Group Randomized Trial Comparing Radiotherapy Alone With Concomitant Radiochemotherapy in Advanced-Stage Oropharynx Carcinoma[J]. Journal of Clinical Oncology, 2004; 22(1):69-76.
[6]. Shibata T . Treatment Planning of IMRT for Head and Neck Malignancies[M]. Springer Japan, 2015.
[7]. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84(1007):967–96.
[8]. Srivastava SP, Cheng CW, Das IJ. The dosimetric and radiobiological impact of calculation grid size on head and neck IMRT. Pract Radiat Oncol. 2017;7(3):209–17.
[9]. Shanmugaratnam K, Chan S H, G de-Thé, et al. Histopathology of nasopharyngeal carcinoma: correlations with epidemiology, survival rates and other biological characteristics[J]. Cancer, 2015; 44(3):1029-1044.
[10]. Zhou X, Ou X, Xu T, Wang X, Shen C, Ding J, et al. Effect of dosimetric factors on occurrence and volume of temporal lobe necrosis following intensity modulated radiation therapy for nasopharyngeal[J]. Radiat Oncol Biol Phys. 2014; 90(2):261–9. 10.1016/j.ijrobp.2014.05.036.
[11]. Ivo Beetz, Roel J H M Steenbakkers, Olga Chouvalova, Johannes A Langendijk, et al. The QUANTEC criteria for parotid gland dose and their efficacy to prevent moderate to severe patient-rated xerostomia. Acta oncologica (Stockholm, Sweden). 53. 10.3109/0284186X.2013.831186.
[12]. Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A: Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011; 84: 967-996. 10.1259/bjr/22373346.
[13]. Rose P G, Bundy B N, Watkins E B, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer[J]. N Engl J Med, 1999; 340(15):1144-1153.
[14]. Fraser I . Quality assurance in radiotherapy[J]. Irish Medical Journal, 1988; 81(1):5.
[15]. Aubry, Jean-Francois & Beaulieu, Frédéric & Sévigny, Caroline & Beaulieu, Luc & Tremblay, Daniel. (2007). Multiobjective optimization with a modified simulated annealing algorithm for external beam radiotherapy treatment planning. Medical physics. 33. 4718-29. 10.1118/1.2390550.
[16]. Cotrutz C, Lahanas M, Kappas C, et al. A multiobjective gradient-based dose optimization algorithm for external beam conformal radiotherapy[J]. Physics in Medicine and Biology, 2001; 46(8):2161-2175.
[17]. Lahanas M, Schreibmann E, Baltas D. Multiobjective inverse planning for intensity modulated radiotherapy with constraint-free gradient-based optimization algorithms[J]. Physics in Medicine & Biology, 2003; 48(17):2843.
[18]. Llacer J, Solberg T D, Promberger C. Comparative behaviour of the dynamically penalized likelihood algorithm in inverse radiation therapy planning[J]. Phys. Med. Biol. 46 2637–63.
[19]. Webb S. Optimizing radiation therapy inverse treatment planning using the simulated annealing technique[J]. International Journal of Imaging Systems & Technology, 2010; 6(1):71-79.
[20]. Freud N. Efficient simulated annealing for full inverse treatment planning[C]. IEEE Nuclear Science Symposium & Medical Imaging Conference. IEEE, 2013; 10.1109/NSSMIC.2013.6829317
[21]. Llacer J, Deasy JO, Portfeld TR, et al.Absence of multiple local minima effects in intensity modulated optimization
with dose-volume constraints[J]. Physics in Medicine & Biology, 2003; 48(2):183-210.
[22]. Llacer J, Agazaryan N, Solberg TD, et al. Degeneracy,frequency response and filtering in IMRT optimization [J]. Phys Med Biol, 2004; 49(13):2853-2880
[23]. Lu WANG, Shuangjun ZHANG, Xiaoxiao ZHAN, et al. The effect of statistical uncertainty on SBRT program in non-small cell lung cancer [J]. Cancer prevention and treatment, 2020; 33(1): 33-40.
[24]. Lee B, Lee S, Sung J, Yoon M. Radiotherapy-induced secondary cancer risk for breast cancer: 3D conformal therapy versus IMRT versus VMAT. J Radiol Prot. 2014;34(2):325–31.
[25]. Kourinou KM, Mazonakis M, Lyraraki E, Stratakis J, Damilakis J. Scattered dose to radiosensitive organs and associated risk for cancer development from head and neck radiotherapy in pediatric patients. Phys Med. 2013;29(6):650–5.
[26]. Lee HF, Lan JH, Chao PJ, Ting HM, Chen HC, Hsu HC, Lee TF. Radiation-induced secondary malignancies for nasopharyngeal carcinoma: a pilot study of patients treated via IMRT or VMAT. Cancer Manag Res. 2018;10:131–41.
[27]. Sakthivel V, Mani GK, Mani S, Boopathy R. Radiation-induced second cancer risk from external beam photon radiotherapy for head and neck cancer: impact on in-field and out-of-field organs. Asian Pac J Cancer Prev. 2017;18(7):1897–903.